Management of Treatment Resistant <scp>EGFR</scp> Inhibitor‐Induced Papulopustular Exanthema With Isotretinoin and Dapsone

Both isotretinoin and dapsone are effective, well-tolerated options for managing tetracycline-resistant EGFRi-induced papulopustular eruptions. Isotretinoin showed a trend toward faster improvement, while ultimate response rates were similar. Maintaining EGFRi therapy, even at reduced doses, in conjunction with dermatology treatment was associated with superior dermatological outcomes and higher survival at follow-up compared with cessation of EGFRi treatment, highlighting the importance of proactive dermatologic intervention to support oncologic treatment continuity.